Immunohistochemistry
Two-micrometer sections were cut and immunostained with the following mouse monoclonal antibodies: OX40 and OX40L (BD Biosciences; Oxford, England) and IL-4 (clones 4D9 and 3H4; AMS Biotechnology; Oxford, England) and IL-4R a (R&D Systems; Abingdon, Oxfordshire, England) in quadruplicate; a -smooth muscle actin (Dako; Cambridge, England ); and major basic protein (Caltag; Paiseley, England) with appropriate isotype controls (Dako ). The number of positively stained nucleated cells was enumerated per square millimeter of the lamina propria or airway smooth muscle (ASM) by a blinded observer. A minimum ASM area of 0.1 mm 2 was considered assessable, as described previously. 14 The number of subjects with adequate smooth muscle was 10/13 controls, 10/10 GINA 1 asthma, 6/7 GINA 2-3 asthma, and 8/10 GINA 4-5 asthma. IL-4R a expression by the ASM was also assessed using a semiquantitative intensity score of no staining 5 0, low 5 1, moderate 5 2, and high 5 3. Post hoc in three subjects with asthma, sequential sections were stained for OX40 and CD3 (T cells), and OX40L and CD1a (dendritic cells). The proportion of the OX40 or OX40L 1 cells that were colocalized to T cells or dendritic cells, respectively, was determined as previously described. 15 
Analysis
Statistical analysis was performed using PRISM software, version 4 (GraphPad Software; La Jolla, CA). Parametric data were presented as mean (SEM) and nonparametric data as median (interquartile range [IQR] ). Parametric data were analyzed with one-way analysis of variance (ANOVA) and Bonferroni's posttest correction for intergroup comparison. Nonparametric data were analyzed using the Kruskal-Wallis tests and Dunn's test for post hoc comparison. The Fisher exact test was used to assess the categorical differences in expression in ASM. Correlations between parametric data were assessed by Pearson's correlation and nonparametric data by Spearman's rank correlation. P , .05 was considered signifi cant.
Results
The baseline clinical characteristics are as shown in Table 1 . The subjects with asthma and the controls were matched for age and gender. Subjects with asthma had a higher BMI compared with controls, and evidence of airway hyperresponsiveness .
Photomicrographs illustrating OX40, OX40L, IL-4, IL-4R a , and the colocalization of OX40, OX40 with T cells, and dendritic cells, respectively, in the lamina propria and their appropriate isotype controls are as shown ( Fig 1 ) . In a subset of asthmatics (n 5 3), we determined that mean (SEM) 56 (6)% of the OX40L 1 cells in the lamina propria were dendritic cells and 94 (6)% of the OX40 1 cells were T cells.
The mean (SEM) number of OX40 1 cells in the lamina propria was signifi cantly increased in subjects with mild corticosteroid-naive (GINA 1) asthma ( promising costimulatory targets is OX40 and its ligand, OX40L, which has relative T-cell specifi city and is not expressed on naive T cells. 3 OX40 is primarily induced on T cells in the effector phase and is predominantly expressed by Th2 cells. 4 In mouse models of allergic infl ammation, OX40 knockout mice have signifi cantly reduced Th2 responses to allergen, accompanied by a reduction in airway eosinophilia and airway hyperreactivity. 5 OX40L is expressed mainly by antigen-presenting cells, particularly dendritic cells, 6 but also B cells, macrophages, and Langerhans cells. 6 In the airway, dendritic cells express OX40L in response to stimulation by epithelial cell-derived thymic stromal lymphopoietin (TSLP). 7 In murine and nonhuman primate models of asthma in vivo, blockade of OX40L inhibits TSLP-mediated Th2 infl ammation and attenuates the number of OX40L 1 dendritic cells in the lung. 8 Whether OX40 and OX40L expression are increased in human airway tissue from subjects with asthma is unknown. We hypothesized that OX40 and OX40L expression is increased in the bronchial lamina propria and that this expression is related to disease severity and Th2 cytokine expression. To test our hypothesis, we enumerated OX40, OX40L, interleukin (IL)-4, and IL-4 receptor a (IL4-R a ) expression in bronchial biopsies from subjects with mild, moderate, and severe asthma, compared with healthy controls.
Materials and Methods

Subjects
Twenty-seven patients with asthma and 13 healthy controls were recruited from Glenfi eld Hospital, Leicester, England. All subjects were nonsmokers with a smoking history of , 10 pack-years, had been free of exacerbations, and were on stable treatment of 8 weeks prior to entry into the study. Asthma was defi ned by one or more of the following objective criteria: significant bronchodilator reversibility of . 200 mL, a provocation concentration of methacholine causing a 20% fall in FEV 1 , 8 mg/mL, and/or a peak fl ow amplitude % mean over 2 weeks of . 20%. Asthma severity was defi ned according to the Global Initiative for Asthma (GINA) treatment steps. 9 Normal subjects had no history of respiratory disease and normal spirometry. The study was approved by the Leicestershire Research Ethics Committee and informed consent was obtained from all subjects.
Protocol and Clinical Characterization
Subjects attended on two occasions. At the fi rst visit, they underwent spirometry; allergen skin prick tests for Dermatophagoides pteronyssinus , dog, cat and grass pollen; a methacholine inhalation test; 10 and sputum induction. 11 At the second visit 1 week later, subjects underwent bronchoscopy. 12 Mucosal biopsy specimens were processed into the water-soluble resin glycol methacrylate (Polysciences; Northampton, England) for embedding. 13 ANOVA; P , .05, control vs GINA 1) ( Fig 2 A ) . Similarly, the number of OX40L 1 cells in the lamina propria was signifi cantly increased in subjects with mild asthma ( P 5 .04, ANOVA; P , .05, control vs GINA 1) ( Fig 2 B ) . The median (IQR) number of OX40 1 cells in the ASM bundle was not signifi cantly different across the groups ( P 5 .08, Kruskal-Wallis), but the proportion of patients with OX40 1 cells in the ASM was signifi cantly increased in mild asthma (5/10), but not in moderate (1/6) or severe asthma (3/8), compared with the controls (0/10) ( P 5 .03, Fisher exact test) (Fig 2 C ) . OX40L 1 cells were not identifi ed within the ASM bundle in health or asthma. There was a strong correlation between the number of OX40 and OX40L 1 cells in the lamina propria (r 5 0.83; P , .0001) ( Fig 2 D ) ( Fig 3 A ) . Similarly, the number of IL-4 (4D9) 1 cells in the lamina propria was signifi cantly increased in subjects with mild asthma ( Fig 3 B ( Figs 3 C , D ) .
In contrast, the mean (SEM) number of IL-4R a 1 cells in the lamina propria was increased in moderate asthma (3.2 [0.9] cells/mm 2 ) and severe asthma (3.1 [0.5] cells/mm 2 ), but not in mild disease (1.9 [0.5] cells/mm 2 ), compared with healthy controls ( P 5 .002, ANOVA) ( Fig 4 A ) . The intensity of IL-4R a expression by ASM was not signifi cantly different between asthma and healthy controls ( P 5 .3, ANOVA) ( Fig 4 B ) .
In the subjects with asthma, OX40 and OX40L expression in the lamina propria was strongly correlated with the IL-4 (3H4) (r 5 0.67, P , .0001 and r 5 0.59, P 5 .001) and (4D9) (r 5 0.48, P 5 .01 and r 5 0.4, P 5 .038) expression, respectively ( Fig 5 ) . The number of OX40 1 cells in the ASM bundle was not significantly correlated with the number of IL-4 1 (3H4 or 4D9) cells (data not shown). We also observed a strong correlation between the number of OX40L 1 cells and eosinophils in the lamina propria (rs 5 0.64, P , .0001), but not with OX40/IL-4 expression (data not shown). There were no signifi cant correlations among OX40, OX40L, or IL-4 expression in the lamina 
Discussion
We report here, to our knowledge for the fi rst time, that the number of OX40 1 and OX40L 1 cells are increased in the lamina propria and OX40 1 cells in the ASM bundle in mild asthma, but not in moderate-tosevere disease. OX40L 1 cells were not observed in the ASM bundle in health or disease. The number of OX40/OX40L cells in the lamina propria was associated with IL-4 expression and eosinophilic infl ammation.
To date, there have been no reports of OX40 or OX40L expression in bronchial submucosal tissue in asthma. Therefore, our observation that OX40 and OX40L expression is increased in mild asthma provides further evidence of a potential role of these molecules in asthma. We identifi ed that the majority of OX40 1 cells were T cells and OX40 L 1 cells were dendritic cells. Previously, animal studies have implicated these costimulatory molecules in the immunopathogenesis of asthma. In mouse models of allergic infl ammation, OX40 knockout mice have signifi cantly reduced Th2 responses to allergen with a reduction in airway eosinophilia and airway hyperreactivity. 5, 16, 17 Dendritic cell-derived OX40L is induced by TSLP, a IL-7-like cytokine produced by epithelial cells, propria or ASM bundle and FEV 1 % predicted, bronchodilator response, or airway hyperresponsiveness (data not shown). Importantly, we were unable to demonstrate increased OX40/OX40L expression in moderate-tosevere disease, in contrast to mild asthma. This may refl ect real differences among disease severities, perhaps as a consequence of treatment. Importantly, the number of subjects included in this study was relatively small and therefore our inability to demonstrate an increase in moderate-to-severe disease may be because of inadequate powering of the study. Furthermore, we may have underestimated OX40 and OX40L expression in asthma, because it may be transient and may increase in response to activation such as allergen challenge. Similarly, the potential benefi ts of therapeutic blockade of OX40/OX40L may depend on sensitization and the duration of post-allergen challenge. In mouse models of asthma, confl icting data exist regarding the most effi cacious time point to neutralize OX40L, with one report suggesting that presensitization alone, and not subsequent challenge, led to a reduction in the asthmatic response, 17 and another fi nding that airway infl ammation was attenuated in postsensitized animals. 30 Therefore, although our inability to demonstrate increased expression which provides an important interaction between the epithelial-dendritic cell. 7 Critically, OX40L neutralization in mouse and nonhuman primate models of asthma inhibited TSLP-induced immune responses, including Th2 infl ammatory cell infi ltration, cytokine secretion, and IgE production 8 . Consistent with these observations, our fi ndings showed a close association between the number of eosinophils and IL-4 expression in the lamina propria and the OX40/OX40L axis. However, in contrast to the animal models, a relationship was not indicated between OX40/OX40L expression and disordered airway physiology, including airway hyperresponsiveness. This dissociation between airway function and Th2-mediated eosinophilic infl ammation is consistent with observations made in noneosinophilic bronchitis 18, 19 and the response to highly specifi c anti-IL-5 therapy. 20, 21 These observations in human disease may challenge a potential role for the OX40/OX40L axis in airway dysfunction in asthma and need to be examined further.
Interestingly, OX40L expression by dendritic cells is also increased by environmental fungal 22 and endotoxin 23 exposure, which have both been implicated in asthma and asthma exacerbations. 24, 25 OX40L production is also not restricted to dendritic cells, because other cells such as ASM may be important potential sources. 26, 27 Ex vivo data in human ASM cells have shown that OX40/OX40L expression was upregulated by tumor necrosis factor-a , and, interestingly, was signifi cantly greater in asthmatic vs nonasthmatic ASM cells. We did not observe OX40/OX40L expression by ASM, but A B C D in severe asthma does question its potential role as a therapeutic target for this group of patients, our fi ndings do not exclude the possibility that the OX40/OX40L axis may be important across all severities of asthma.
In keeping with the OX40/OX40L expression, IL-4 upregulation was restricted to those subjects with mild disease. This is consistent with an earlier report, 31 but is in stark contrast to IL-13 expression, which resulted in an increase in the sputum and bronchial mucosa of severe asthmatics. 32, 33 Interestingly, the number of IL-4R a 1 cells was increased in the lamina propria in moderate-to-severe disease, with a small, nonsignifi cant increase in mild asthmatics. This differential expression of IL-4 and IL-13 in severe disease has important implications for potential therapeutic strategies in severe asthma directed toward either cytokine neutralization 34, 35 or receptor antagonism. 36 In addition, the balance between the expression of cytokines and their receptors in severe disease is likely to be clinically important and requires further consideration.
Conclusions
In conclusion, we have shown that the OX40/ OX40L axis is upregulated in mild asthma. But not in moderate-tosevere disease, and is related to the intensity of IL-4 expression and eosinophilic infl ammation. Whether these costimulatory molecules present new therapeutic targets for asthma, and how we can determine which severity of asthma and what stage of the natural history of disease may benefi t, require further investigation.
